188 related articles for article (PubMed ID: 32783304)
1. DNA methylation analysis with methylation-sensitive high-resolution melting (MS-HRM) reveals gene panel for glioma characteristics.
Majchrzak-Celińska A; Dybska E; Barciszewska AM
CNS Neurosci Ther; 2020 Dec; 26(12):1303-1314. PubMed ID: 32783304
[TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
3. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
4. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
5. Wnt pathway antagonists, SFRP1, SFRP2, SOX17, and PPP2R2B, are methylated in gliomas and SFRP1 methylation predicts shorter survival.
Majchrzak-Celińska A; Słocińska M; Barciszewska AM; Nowak S; Baer-Dubowska W
J Appl Genet; 2016 May; 57(2):189-97. PubMed ID: 26337424
[TBL] [Abstract][Full Text] [Related]
6. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
[TBL] [Abstract][Full Text] [Related]
7. The association between
Okita Y; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Kinoshita M; Nonaka M; Fujinaka T; Kanemura Y
Clin Radiol; 2020 Aug; 75(8):622-628. PubMed ID: 32321646
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
10. Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
Buttarelli FR; Massimino M; Antonelli M; Lauriola L; Nozza P; Donofrio V; Arcella A; Oliva MA; Di Rocco C; Giangaspero F
Childs Nerv Syst; 2010 Aug; 26(8):1051-6. PubMed ID: 20552207
[TBL] [Abstract][Full Text] [Related]
11. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.
Moon WJ; Choi JW; Roh HG; Lim SD; Koh YC
Neuroradiology; 2012 Jun; 54(6):555-63. PubMed ID: 21833736
[TBL] [Abstract][Full Text] [Related]
12. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas.
Wang L; Li Z; Liu C; Chen L; Liu L; Hu Z; Zhao L; Lu D; Teng L
Pathol Res Pract; 2017 Dec; 213(12):1489-1493. PubMed ID: 29103769
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of the RASSF1A gene in gliomas.
Gao Y; Guan M; Su B; Liu W; Xu M; Lu Y
Clin Chim Acta; 2004 Nov; 349(1-2):173-9. PubMed ID: 15469871
[TBL] [Abstract][Full Text] [Related]
17. MGMT promoter methylation in plasma of glioma patients receiving temozolomide.
Fiano V; Trevisan M; Trevisan E; Senetta R; Castiglione A; Sacerdote C; Gillio-Tos A; De Marco L; Grasso C; Magistrello M; Tondat F; Rudà R; Cassoni P; Soffietti R; Merletti F
J Neurooncol; 2014 Apr; 117(2):347-57. PubMed ID: 24519517
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast.
Huang KT; Dobrovic A; Yan M; Karim RZ; Lee CS; Lakhani SR; Fox SB
Breast Cancer Res Treat; 2010 Nov; 124(2):555-65. PubMed ID: 20563638
[TBL] [Abstract][Full Text] [Related]
19. DAPK1, MGMT and RARB promoter methylation as biomarkers for high-grade cervical lesions.
Sun Y; Li S; Shen K; Ye S; Cao D; Yang J
Int J Clin Exp Pathol; 2015; 8(11):14939-45. PubMed ID: 26823825
[TBL] [Abstract][Full Text] [Related]
20. [Detection of O6-methylguanine-DNA methyltransferase promoter methylation in chemotherapy for glioma].
Zheng CQ; Ji SP; Gong F; Li AM; Tai JL; Zhang YP
Ai Zheng; 2009 Jun; 28(6):575-80. PubMed ID: 19635193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
